packageCamrelizumab

camrelizumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Camrelizumab is a PD-1 inhibitor monoclonal antibody being investigated as an anticancer agent. It is not authorised in the European Union and remains investigational.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification; not checked by a person.

name:camrelizumab
ATC codes:L01FF14
DrugBank:DB14776

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown